Cradle

About Cradle

Cradle is at the forefront of developing groundbreaking cryopreservation technologies aimed at pausing biological time for those in critical need. The company focuses on reversible cryopreservation of living tissues, with a vision to extend this capability to whole human organs and neural tissues. This technology has the potential to revolutionize organ transplantation by providing better-matched organs and aiding neuroscience research by preserving neural tissues. Cradle operates in the biotechnology sector, targeting medical researchers, healthcare providers, and patients with severe medical conditions. The business model revolves around research and development, funded by a significant capital raise of $48 million, and aims to generate revenue through the commercialization of its cryopreservation technologies. The company’s recent milestone includes successfully recovering electrical activity in cryopreserved and rewarmed rodent neural tissue, marking a significant step towards their ultimate goal of whole-body cryopreservation. Cradle's roadmap includes achieving key milestones in cryopreservation at medically relevant biological scales, with plans to release data for each milestone achieved.